Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TKNO
stocks logo

TKNO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.62M
+3.82%
-0.092
-16.36%
10.68M
+8.98%
-0.087
-2.78%
11.14M
+8.3%
-0.080
+14.29%
Estimates Revision
The market is revising Downward the revenue expectations for Alpha Teknova, Inc. (TKNO) for FY2025, with the revenue forecasts being adjusted by -0.81% over the past three months. During the same period, the stock price has changed by 10.78%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.81%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.07%
In Past 3 Month
Stock Price
Go Up
up Image
+10.78%
In Past 3 Month
Wall Street analysts forecast TKNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TKNO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TKNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TKNO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.830
sliders
Low
7.00
Averages
7.00
High
7.00
Current: 4.830
sliders
Low
7.00
Averages
7.00
High
7.00
Stephens
Stephens
maintain
$8
2025-07-21
Reason
Stephens
Stephens
Price Target
$8
2025-07-21
maintain
Reason
Stephens resumed coverage of Alpha Teknova with an Overweight rating and $8 price target. The company will benefit from growth in the biologics end market, the analyst tells investors in a research note. The firm believes Alpha continues to add to its clinical solutions customer base, which should drive revenue growth as demand ramps.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alpha Teknova Inc (TKNO.O) is -14.23, compared to its 5-year average forward P/E of -11.82. For a more detailed relative valuation and DCF analysis to assess Alpha Teknova Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.82
Current PE
-14.23
Overvalued PE
-0.68
Undervalued PE
-22.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.26
Undervalued EV/EBITDA
-38.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.45
Current PS
0.00
Overvalued PS
11.02
Undervalued PS
1.89
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TKNO News & Events

Events Timeline

(ET)
2025-11-06
16:25:34
Alpha Teknova Supports FY25 Revenue Forecast of $39M-$42M, Aligning with Consensus of $40.61M
select
2025-11-06
16:24:31
Alpha Teknova Announces Q3 Earnings Per Share of 8 Cents, Below Consensus Estimate of 9 Cents
select
2025-08-14 (ET)
2025-08-14
08:30:08
new option listings on August 14th
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-07NASDAQ.COM
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.0
09-25NASDAQ.COM
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation

  • Biotech Stock Performance: Several biotech stocks, including PepGen and Immuneering, experienced significant gains due to positive clinical trial results, with PepGen's stock soaring 36% during regular trading and an additional 134% in after-hours trading following promising data for its myotonic dystrophy treatment.

  • Clinical Trial Updates: Immuneering reported an impressive overall survival rate of 86% in its pancreatic cancer trial, while other companies like Clearmind Medicine and Jasper Therapeutics also saw stock increases based on ongoing clinical evaluations and positive preliminary results.

  • Market Developments: ClearPoint Neuro's stock surged over 58% after receiving FDA clearance for its laser therapy system, expanding its market potential, while Neuphoria Therapeutics anticipates topline results from its social anxiety disorder trial in early Q4 2025.

  • Investor Interest: The overall investor interest in biotech stocks is reflected in the significant price movements of various companies, driven by clinical trial advancements and strategic opportunities, indicating a robust market for biotech innovations.

[object Object]
Preview
4.0
09-20TipRanks
Experts Forecast Potential 840% Surge for These 2 'Strong Buy' Penny Stocks

  • Penny Stocks vs. Mega-Cap Stocks: While large companies like Nvidia dominate the stock market, penny stocks (priced below $5) offer significant growth potential, with the possibility of triple-digit percentage gains, though investors must be cautious due to inherent risks.

  • Highlighted Penny Stocks: Two penny stocks, Protara Therapeutics (TARA) and Alpha Teknova (TKNO), have received strong buy ratings from analysts, with TARA showing potential for an 840% increase and TKNO for a 159% increase, driven by promising clinical developments and market positioning.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alpha Teknova Inc (TKNO) stock price today?

The current price of TKNO is 4.83 USD — it has increased 0.42 % in the last trading day.

arrow icon

What is Alpha Teknova Inc (TKNO)'s business?

Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary product categories, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. It supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and others, with catalog and custom, made-to-order products.

arrow icon

What is the price predicton of TKNO Stock?

Wall Street analysts forecast TKNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TKNO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alpha Teknova Inc (TKNO)'s revenue for the last quarter?

Alpha Teknova Inc revenue for the last quarter amounts to 10.45M USD, increased 9.17 % YoY.

arrow icon

What is Alpha Teknova Inc (TKNO)'s earnings per share (EPS) for the last quarter?

Alpha Teknova Inc. EPS for the last quarter amounts to -0.08 USD, decreased -46.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alpha Teknova Inc (TKNO)'s fundamentals?

The market is revising Downward the revenue expectations for Alpha Teknova, Inc. (TKNO) for FY2025, with the revenue forecasts being adjusted by -0.81% over the past three months. During the same period, the stock price has changed by 10.78%.
arrow icon

How many employees does Alpha Teknova Inc (TKNO). have?

Alpha Teknova Inc (TKNO) has 173 emplpoyees as of December 05 2025.

arrow icon

What is Alpha Teknova Inc (TKNO) market cap?

Today TKNO has the market capitalization of 257.48M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free